Jefferies Financial Group Inc. Increases Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Jefferies Financial Group Inc. lifted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 140.4% in the 4th quarter, Holdings Channel reports. The firm owned 887,497 shares of the company’s stock after purchasing an additional 518,300 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Apogee Therapeutics were worth $40,204,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Driehaus Capital Management LLC raised its stake in shares of Apogee Therapeutics by 2.8% in the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock valued at $118,021,000 after acquiring an additional 71,703 shares during the period. Alliancebernstein L.P. raised its position in shares of Apogee Therapeutics by 13.5% during the 4th quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock worth $61,390,000 after purchasing an additional 160,822 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Apogee Therapeutics by 38.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company’s stock worth $47,683,000 after acquiring an additional 294,514 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in Apogee Therapeutics by 40.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company’s stock valued at $42,207,000 after acquiring an additional 267,530 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Apogee Therapeutics by 0.6% during the 4th quarter. Franklin Resources Inc. now owns 866,188 shares of the company’s stock worth $39,238,000 after buying an additional 5,199 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Carl Dambkowski sold 2,725 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $35.75, for a total transaction of $97,418.75. Following the sale, the insider now directly owns 244,448 shares in the company, valued at approximately $8,739,016. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the transaction, the chief executive officer now owns 1,292,987 shares of the company’s stock, valued at $38,983,558.05. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,175 shares of company stock valued at $587,191. 36.10% of the stock is owned by company insiders.

Analyst Ratings Changes

APGE has been the subject of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Citigroup began coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $95.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $94.60.

Apogee Therapeutics Stock Down 1.4 %

Shares of Apogee Therapeutics stock opened at $37.29 on Friday. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50. The stock has a 50 day moving average price of $36.26 and a two-hundred day moving average price of $41.58. The stock has a market capitalization of $1.67 billion, a P/E ratio of -15.41 and a beta of 1.70.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.